Larsson-Backström C, Arrhenius E, Sagge K
Acta Pharmacol Toxicol (Copenh). 1985 Jul;57(1):8-17. doi: 10.1111/j.1600-0773.1985.tb00002.x.
Studies were carried out on the Ca-antagonistic effects of terodiline and its enantiomers on the potassium-stimulated mesenteric and coronary arteries, on the spontaneous myogenic activity and norepinephrine- and acetylcholine-induced contractions of the protal vein and on electrically stimulated papillary muscle. The effects were compared with those of the Ca-antagonists, nifedipine and verapamil. Terodiline is relatively weak as a Ca-antagonist, having IC50-values between 5 X 10(-6) and 2 X 10(-5)M for all the tissues studied. Nifedipine is the most potent Ca-antagonist on vascular smooth muscle (IC50 3-6 X 10(-9) M), but is considerably less potent on the papillary muscle (IC50 10(-7)M). Verapamil is most potent on the papillary muscle (IC50 7 X 10(-8)M and the portal vein (IC50 6 X 10(-8)M, but is 10 times less potent on the mesenteric and coronary arteries (IC50 3-5 X 10(-7)M). Nifedipine is 1000 times and verapamil and (-)-terodiline 10 times more potent on the slow component of the K-induced contraction while (+/-)- and (+)-terodiline are almost as active on the fast as on the slow component of K-induced contractions on the mesenteric artery. Furthermore, (+/-)-and (+)-terodiline are 10 times more potent in antagonizing acetylcholine- and norepinephrine-induced contractions, whereas (-)-terodiline is equally potent and nifedipine and verapamil are 10 times more potent in blocking the myogenic activity of the portal vein. On the Ca2+-nifedipine and verapamil. However, nifedipine and verapamil, but not terodiline, in concentrations which blocked the maximal norepinephrine-induced response in non-depleted muscle, antagonized the contractions induced by norepinephrine together with Ca2+ in the Ca2+ depleted portal vein. These results show that terodiline blocks the uptake of Ca2+ and, in addition, blocks the utilization of some intracellular stores of Ca2+.
研究了特罗地林及其对映体对钾离子刺激的肠系膜动脉和冠状动脉的钙拮抗作用,对门静脉自发肌源性活动以及去甲肾上腺素和乙酰胆碱诱导的收缩的作用,以及对电刺激乳头肌的作用。并将这些作用与钙拮抗剂硝苯地平和维拉帕米的作用进行了比较。特罗地林作为一种钙拮抗剂相对较弱,在所研究的所有组织中,其半数抑制浓度(IC50)值在5×10⁻⁶至2×10⁻⁵M之间。硝苯地平对血管平滑肌是最有效的钙拮抗剂(IC50为3 - 6×10⁻⁹M),但对乳头肌的效力则低得多(IC50为10⁻⁷M)。维拉帕米对乳头肌(IC50为7×10⁻⁸M)和门静脉(IC50为6×10⁻⁸M)最有效,但对肠系膜动脉和冠状动脉的效力则低10倍(IC50为3 - 5×10⁻⁷M)。硝苯地平对钾离子诱导收缩的慢成分的效力是特罗地林的1000倍,维拉帕米和(-)-特罗地林是其10倍,而(±)-和(+)-特罗地林对肠系膜动脉钾离子诱导收缩的快成分和慢成分的活性几乎相同。此外,(±)-和(+)-特罗地林在拮抗乙酰胆碱和去甲肾上腺素诱导的收缩方面效力高10倍,而(-)-特罗地林效力相当,硝苯地平和维拉帕米在阻断门静脉肌源性活动方面效力高10倍。在钙离子耗尽的门静脉中,硝苯地平和维拉帕米(但不是特罗地林)在能阻断未耗尽肌肉中最大去甲肾上腺素诱导反应的浓度下,能拮抗去甲肾上腺素与钙离子一起诱导的收缩。这些结果表明,特罗地林可阻断钙离子的摄取,此外,还可阻断一些细胞内钙储备的利用。